|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival|
TJ Curiel, G Coukos, L Zou, X Alvarez, P Cheng, P Mottram, ...
Nature medicine 10 (9), 942-949, 2004
|Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion|
H Dong, SE Strome, DR Salomao, H Tamura, F Hirano, DB Flies, ...
Nature medicine 8 (8), 793-800, 2002
|Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates|
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167, 2010
|Molecular mechanisms of T cell co-stimulation and co-inhibition|
L Chen, DB Flies
Nature reviews immunology 13 (4), 227-242, 2013
|B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion|
H Dong, G Zhu, K Tamada, L Chen
Nature medicine 5 (12), 1365-1369, 1999
|Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy|
JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ...
Clinical cancer research 20 (19), 5064-5074, 2014
|Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape|
JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ...
Science translational medicine 4 (127), 127ra37-127ra37, 2012
|PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations|
W Zou, JD Wolchok, L Chen
Science translational medicine 8 (328), 328rv4-328rv4, 2016
|Inhibitory B7-family molecules in the tumour microenvironment|
W Zou, L Chen
Nature Reviews Immunology 8 (6), 467-477, 2008
|Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity|
Nature Reviews Immunology 4 (5), 336-347, 2004
|Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity|
TJ Curiel, S Wei, H Dong, X Alvarez, P Cheng, P Mottram, R Krzysiek, ...
Nature medicine 9 (5), 562-567, 2003
|Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4|
L Chen, S Ashe, WA Brady, I Hellström, KE Hellström, JA Ledbetter, ...
Cell 71 (7), 1093-1102, 1992
|Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future|
L Chen, X Han
The Journal of clinical investigation 125 (9), 3384-3391, 2015
|Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity|
F Hirano, K Kaneko, H Tamura, H Dong, S Wang, M Ichikawa, C Rietz, ...
Cancer research 65 (3), 1089-1096, 2005
|B7-H3: a costimulatory molecule for T cell activation and IFN-γ production|
AI Chapoval, J Ni, JS Lau, RA Wilcox, DB Flies, D Liu, H Dong, GL Sica, ...
Nature immunology 2 (3), 269-274, 2001
|Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors|
I Melero, WW Shuford, SA Newby, A Aruffo, JA Ledbetter, KE Hellström, ...
Nature medicine 3 (6), 682-685, 1997
|A paradigm shift in cancer immunotherapy: from enhancement to normalization|
MF Sanmamed, L Chen
Cell 175 (2), 313-326, 2018
|Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target|
RH Thompson, MD Gillett, JC Cheville, CM Lohse, H Dong, WS Webster, ...
Proceedings of the National Academy of Sciences 101 (49), 17174-17179, 2004
|B7-H4, a molecule of the B7 family, negatively regulates T cell immunity|
GL Sica, IH Choi, G Zhu, K Tamada, SD Wang, H Tamura, AI Chapoval, ...
Immunity 18 (6), 849-861, 2003